Display options
Cite
Strand SH, Hoyer S, Lynnerup AS, et al. High levels of 5-hydroxymethylcytosine (5hmC) is an adverse predictor of biochemical recurrence after prostatectomy in ERG-negative prostate cancer. Clin Epigenetics. 2015;7:111doi: 10.1186/s13148-015-0146-5.
Strand, S. H., Hoyer, S., Lynnerup, A. S., Haldrup, C., Storebjerg, T. M., Borre, M., Orntoft, T. F., & Sorensen, K. D. (2015). High levels of 5-hydroxymethylcytosine (5hmC) is an adverse predictor of biochemical recurrence after prostatectomy in ERG-negative prostate cancer. Clinical epigenetics, 7111. https://doi.org/10.1186/s13148-015-0146-5
Strand, Siri H, et al. "High levels of 5-hydroxymethylcytosine (5hmC) is an adverse predictor of biochemical recurrence after prostatectomy in ERG-negative prostate cancer." Clinical epigenetics vol. 7 (2015): 111. doi: https://doi.org/10.1186/s13148-015-0146-5
Strand SH, Hoyer S, Lynnerup AS, Haldrup C, Storebjerg TM, Borre M, Orntoft TF, Sorensen KD. High levels of 5-hydroxymethylcytosine (5hmC) is an adverse predictor of biochemical recurrence after prostatectomy in ERG-negative prostate cancer. Clin Epigenetics. 2015 Oct 15;7:111. doi: 10.1186/s13148-015-0146-5. eCollection 2015. PMID: 26478752; PMCID: PMC4608326.
Copy Download .nbib Format: NLM
Share it on

Clin Epigenetics. 2015 Oct 15;7:111. doi: 10.1186/s13148-015-0146-5. eCollection 2015.

High levels of 5-hydroxymethylcytosine (5hmC) is an adverse predictor of biochemical recurrence after prostatectomy in ERG-negative prostate cancer.

Clinical epigenetics

Siri H Strand, Soren Hoyer, Anne-Sofie Lynnerup, Christa Haldrup, Tine Maj Storebjerg, Michael Borre, Torben F Orntoft, Karina D Sorensen

Affiliations

  1. Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark.
  2. Department of Histopathology, Aarhus University Hospital, Aarhus, Denmark.
  3. Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark ; Department of Histopathology, Aarhus University Hospital, Aarhus, Denmark ; Department of Urology, Aarhus University Hospital, Aarhus, Denmark.
  4. Department of Urology, Aarhus University Hospital, Aarhus, Denmark.

PMID: 26478752 PMCID: PMC4608326 DOI: 10.1186/s13148-015-0146-5

Abstract

BACKGROUND: Prostate cancer (PC) can be stratified into distinct molecular subtypes based on TMPRSS2-ERG gene fusion status, but its potential prognostic value remains controversial. Likewise, routine clinicopathological features cannot clearly distinguish aggressive from indolent tumors at the time of diagnosis; thus, new prognostic biomarkers are urgently needed. The DNA methylation variant 5-hydroxymethylcytosine (5hmC, an oxidized derivative of 5-methylcytosine) has recently emerged as a new diagnostic and/or prognostic biomarker candidate for several human malignancies. However, this remains to be systematically investigated for PC. In this study, we determined 5hmC levels in 311 PC (stratified by ERG status) and 228 adjacent non-malignant (NM) prostate tissue specimens by immunohistochemical analysis of a tissue microarray, representing a large radical prostatectomy (RP) cohort with long clinical follow-up. We investigated possible correlations between 5hmC and routine clinicopathological variables and assessed the prognostic potential of 5hmC by Kaplan-Meier and uni- and multivariate Cox regression analyses in ERG+ (n = 178) vs. ERG- (n = 133) PCs using biochemical recurrence (BCR) as endpoint.

RESULTS: We observed a borderline significant (p = 0.06) reduction in 5hmC levels in PC compared to NM tissue samples, which was explained by a highly significant (p < 0.001) loss of 5hmC in ERG- PCs. ERG status was not predictive of BCR in this cohort (p = 0.73), and no significant association was found between BCR and 5hmC levels in ERG+ PCs (p = 0.98). In contrast, high 5hmC immunoreactivity was a significant adverse predictor of BCR after RP in ERG- PCs, independent of Gleason score, pathological tumor stage, surgical margin status, and pre-operative prostate-specific antigen (PSA) level (hazard ratio (HR) (95 % confidence interval (CI)): 1.62 (1.15-2.28), p = 0.006).

CONCLUSIONS: This is the first study to demonstrate a prognostic potential for 5hmC in PC. Our findings highlight the importance of ERG stratification in PC biomarker studies and suggest that epigenetic mechanisms involving 5hmC are important for the development and/or progression of ERG- PC.

Keywords: 5-hydroxymethylation; 5hmC; Biomarker; DNA methylation; ERG; Epigenetics; Prognostic; Prostate cancer

References

  1. Eur Urol. 2015 Dec;68(6):1033-44 - PubMed
  2. PLoS One. 2012;7(7):e41036 - PubMed
  3. Cancer Lett. 2014 Jan 28;342(2):248-56 - PubMed
  4. PLoS One. 2010 Dec 23;5(12):e15367 - PubMed
  5. Cell Rep. 2014 Jun 12;7(5):1343-52 - PubMed
  6. Genome Biol. 2014 Dec 03;15(12 ):513 - PubMed
  7. Science. 2011 Sep 2;333(6047):1303-7 - PubMed
  8. J Nucleic Acids. 2011;2011:870726 - PubMed
  9. Int J Cancer. 2009 Jul 15;125(2):353-5 - PubMed
  10. Lancet Oncol. 2008 Apr;9(4):342-51 - PubMed
  11. Br J Cancer. 2013 Feb 5;108(2):420-8 - PubMed
  12. Biometrics. 2008 Mar;64(1):10-9 - PubMed
  13. Clin Cancer Res. 2014 Apr 15;20(8):2169-81 - PubMed
  14. Urol Oncol. 2013 Jul;31(5):622-7 - PubMed
  15. Clin Cancer Res. 2012 May 15;18(10 ):2896-904 - PubMed
  16. J Biomed Nanotechnol. 2013 Sep;9(9):1607-16 - PubMed
  17. Cell Cycle. 2013 Jun 15;12(12):1835-41 - PubMed
  18. Am J Surg Pathol. 2005 Sep;29(9):1228-42 - PubMed
  19. Cancer Sci. 2012 Apr;103(4):670-6 - PubMed
  20. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2014 Dec;158(4):502-10 - PubMed
  21. Oncogene. 2016 Jan 28;35(4):403-14 - PubMed
  22. Cancer Res. 2014 Jun 15;74(12):3228-37 - PubMed
  23. Neoplasia. 2010 Jul;12 (7):590-8 - PubMed
  24. Science. 2011 Sep 2;333(6047):1300-3 - PubMed
  25. Int J Mol Sci. 2014 Sep 18;15(9):16544-76 - PubMed
  26. Cancer Biol Ther. 2014 Jan;15(1):10-5 - PubMed
  27. Blood. 2014 Aug 14;124(7):1110-8 - PubMed
  28. Clin Cancer Res. 2013 Jul 1;19(13):3450-61 - PubMed
  29. Cancer Res. 2010 Nov 15;70(22):8994-9002 - PubMed
  30. Eur Urol. 2015 Oct;68(4):555-67 - PubMed
  31. Biochim Biophys Acta. 2015 Apr;1855(2):144-54 - PubMed
  32. J Clin Oncol. 2013 Sep 10;31(26):3250-8 - PubMed
  33. Genome Biol. 2013;14(10):R119 - PubMed
  34. Nat Genet. 2012 May 20;44(6):685-9 - PubMed
  35. Oncogene. 2013 Jan 31;32(5):663-9 - PubMed
  36. Oncotarget. 2011 Aug;2(8):627-37 - PubMed
  37. BMC Cancer. 2011 Dec 05;11:507 - PubMed
  38. PLoS One. 2010 Jan 26;5(1):e8888 - PubMed
  39. Nature. 2010 Aug 26;466(7310):1129-33 - PubMed
  40. Cancer Cell. 2008 Jun;13(6):519-28 - PubMed
  41. J Natl Cancer Inst. 2015 May 08;107(8):null - PubMed
  42. Nat Methods. 2014 Jun;11(6):599-600 - PubMed
  43. PLoS One. 2013 Dec 26;8(12 ):e82881 - PubMed
  44. J Clin Exp Hematop. 2014;54(1):67-73 - PubMed
  45. Prostate Cancer Prostatic Dis. 2012 Jun;15(2):165-9 - PubMed
  46. Nature. 2010 Dec 9;468(7325):839-43 - PubMed
  47. Genome Res. 2012 Mar;22(3):467-77 - PubMed
  48. J Urol. 2007 Mar;177(3):822-31 - PubMed
  49. Eur Urol. 2013 Dec;64(6):941-50 - PubMed
  50. Cell. 2012 Sep 14;150(6):1135-46 - PubMed
  51. Science. 2009 May 15;324(5929):930-5 - PubMed
  52. JAMA. 2005 May 4;293(17):2095-101 - PubMed
  53. Science. 2005 Oct 28;310(5748):644-8 - PubMed
  54. Cancer Res. 2011 Dec 15;71(24):7360-5 - PubMed
  55. Int J Cancer. 2012 Oct 1;131(7):1577-90 - PubMed
  56. Nat Struct Mol Biol. 2015 Sep;22(9):656-61 - PubMed
  57. Leuk Lymphoma. 2013 Nov;54(11):2466-73 - PubMed
  58. Cell Death Dis. 2014 Apr 17;5:e1183 - PubMed
  59. Genome Biol. 2015 Apr 01;16:69 - PubMed

Publication Types